Search Results

You searched for : Empagliflozin

	CDSCO has approved Boehringer Ingelheim's Jardiance for the treatment of heart failure. ... May 20
	US FDA approves Jardiance (empagliflozin) to treat adults living with heart failure with reduced ejection fraction Latest Pharma News Update... Aug 23
	Lupin Receives Tentative Approval for Empagliflozin and Metformin Hydrochloride ER Tablets Empagliflozin and Metformin Hydrochloride Extended-Release (ER) Tablets, are indicated as an adjunct to diet and exercise, to improve glycemic control in adults with type ... Jan 07
	Empagliflozin reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME trial ... Nov 19
	Alembic Pharma receives USFDA tentative approval for Empagliflozin and Linagliptin tablets Empagliflozin and Linagliptin tablets, have an estimated market size of US$ 244 million for twelve months ending June 2020... Aug 27
	Alembic Pharmaceuticals receives USFDA approval for Vardenafil Hydrochloride tablets Alembic receives USFDA approval for their erectile dysfunction drug ... Aug 05
	USFDA gives tentative nod to Zydus for Empagliflozin tablets The medication is used to improve blood sugar control in adults with Type 2 diabetes mellitus, along with diet and exercise.... Apr 13
	Consistent cardiovascular benefits shown with empagliflozin treatment regardless of the number of controlled cardiovascular risk factors Post-hoc analysis of the EMPA-REG OUTCOMEÂ® trial in adults with type 2 diabetes and established cardiovascular disease examined the cardiovascular benefits of empagliflozin ... Sep 20
8 Matching result(s) found!

-Advertisements-

Trending Now
	EV Conference 24---Charging Up for e-mobility Minister Ponnam Prabhakar and Jayesh Ranjan among others to graceJune 14, 2024
	Are we on track to end AIDS, end viral hepatitis and end STIs by 2030?June 14, 2024
	HR Conclave Focusing on Future-Forward Engineering where Engineering and Management students meet their future employees, thus exposing students to real-world HR challenges and innovative solutionsJune 14, 2024
	MAGGI Empowers 10 Women to Bring their Entrepreneurial dreams to lifeJune 13, 2024
	FTCCI announced its Annual Excellence Awards and invites entries, last date is 20th June 2024June 13, 2024
	Bird Flu Cases by Dr Praveen Gupta, Principle Director and Chief of Neurology, Fortis Hospital.June 13, 2024
	Sova Health's $1 Million Seed Funding to Drive Gut Health InnovationJune 13, 2024
	The Vital Role of Early Detection: Kevin Jonas on Battling Skin CancerJune 13, 2024
	Zumutor Biologics Advances Cancer Care with Novel Immunotherapy ZM008: A First-in-Class Anti LLT1 AntibodyJune 13, 2024
	HP Ghosh Hospital Unveils Innovative "Chest Tree" June 12, 2024
	Olympus Enhances Innovation Capabilities by Expanding R&D to Hyderabad, IndiaJune 12, 2024
	From the frontlines: Homeless person won over alcoholism, survived floods and defeated TBJune 12, 2024
	The Role of Hormones in Obesity: Why Men and Women Gain Weight DifferentlyJune 12, 2024
	Silent Killer: How a Young Mother’s Vision Loss Led to a Lung Cancer DiagnosisJune 12, 2024
	TruAlt Bioenergy’s subsidiary, Leafiniti Bioenergy supplies over 1000 tons of Compressed Biogas to AG&P Pratham in just 5 monthsJune 11, 2024
	Southeast Asia's Most Advanced Luxury Postpartum Centre Re'Joy Suites Opens in SingaporeJune 11, 2024
	Poor Muscle Health in Obesity Can be A Major Risk Factor for Early DeathJune 11, 2024
	Machine Learning Uncovers How Organ Ageing Impacts Health and LongevityJune 11, 2024
	Why Education is Essential for Health and LongevityJune 11, 2024
	New Study Reveals Antidepressant Withdrawal Symptoms Less Common but Still SignificantJune 10, 2024

Search Results

CDSCO has approved Boehringer Ingelheim's Jardiance for the treatment of heart failure.

US FDA approves Jardiance (empagliflozin) to treat adults living with heart failure with reduced ejection fraction

Lupin Receives Tentative Approval for Empagliflozin and Metformin Hydrochloride ER Tablets

Empagliflozin reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME trial

Alembic Pharma receives USFDA tentative approval for Empagliflozin and Linagliptin tablets

Alembic Pharmaceuticals receives USFDA approval for Vardenafil Hydrochloride tablets

USFDA gives tentative nod to Zydus for Empagliflozin tablets

Consistent cardiovascular benefits shown with empagliflozin treatment regardless of the number of controlled cardiovascular risk factors

Trending Now